Expertise in
13
conditions

Dr. Mitchell Machtay

Radiation Oncology
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
13
conditions
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 

Overview

Mitchell Machtay is a Radiation Oncologist practicing medicine in Hershey, Pennsylvania.

Dr. Machtay is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 131 peer reviewed articles and participating in 19 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in OH

Hospital Affiliations

Milton S Hershey Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

The Milton S. Hershey Medical Center
500 University Dr, Hershey, PA 17033
Other Locations
University Hospitals
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
View 8 Less Clinical Trials

131 Total Publications

Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors.
Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors.
Journal: Molecular pharmaceutics
Published: February 17, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Joseph Miccio
Radiation Oncology
Expertise in
9
conditions
Dr. Joseph Miccio
Radiation Oncology

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances

Joseph Miccio is a Radiation Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Miccio is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Pleuropulmonary Blastoma.

Expertise in
26
conditions
Dr. Leonard Tuanquin
Radiation Oncology
Expertise in
26
conditions
Dr. Leonard Tuanquin
Radiation Oncology

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
717-531-8024
Languages Spoken:
English
See accepted insurances

Leonard Tuanquin is a Radiation Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Tuanquin is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Posterior Fossa Tumor, Embryonal Tumor with Multilayered Rosettes, Gliosarcoma, and Atypical Teratoid Rhabdoid Tumor (ATRT).

Expertise in
29
conditions
Dr. Nimisha Deb
Radiation Oncology
Expertise in
29
conditions
Dr. Nimisha Deb
Radiation Oncology

Wellspan Radiation Oncology-Sechler Family Cancer Center

844 Tuck St, 
Lebanon, PA 
 (14.2 miles away)
717-270-2238
Languages Spoken:
English
See accepted insurances

Nimisha Deb is a Radiation Oncologist practicing medicine in Lebanon, Pennsylvania. Dr. Deb is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Meningioma, Posterior Fossa Tumor, Anal Cancer, and Primitive Neuroectodermal Tumor (PNET).

Frequently Asked Questions about Dr. Mitchell Machtay

How do I make an appointment with Dr. Mitchell Machtay?

You can book an appointment with Dr. Mitchell Machtay by calling their office at 800-243-1455. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mitchell Machtay a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mitchell Machtay is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mitchell Machtay specialize in?

While Dr. Mitchell Machtay is a Radiation Oncology, they have specific expertise in Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Mitchell Machtay participate in research or clinical trials?

Yes. Dr. Mitchell Machtay has published 131 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Mitchell Machtay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mitchell Machtay accept my insurance?

Dr. Mitchell Machtay accepts most major insurance plans, including Cigna and Gateway Health Plan. We recommend calling the office directly at 800-243-1455 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Machtay's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile